Source: Eur Respir Monogr 2011; 51: 218-235
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kupczyk, S. Lundström, B. Dahlén, D. Balgoma, C.E. Wheelock, S-E. Dahlén. Lipid mediators in severe asthma. Eur Respir Monogr 2011; 51: 218-235

Member's Comments

No comment yet.

Related content which might interest you: An update on anti-inflammatory endogenous mediators Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Lipoxins and related anti-inflammatory eicosanoids Source: Annual Congress 2007 - Eicosanoids in inflammation: new findings Year: 2007 Imbalance of anti-inflammatory (lipoxin A4) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. Source: International Congress 2014 – Airway biomarkers Year: 2014 Endogenous lipid mediators in the resolution of airway inflammation Source: Eur Respir J 2007; 30: 980-992 Year: 2007 Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003 Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis Source: Eur Respir J 2005; 26: 1069-1073 Year: 2005 Chronic inflammation in asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=126 Year: 2003 Evaluation of lipoxin A4 and nitric oxide as inflammatory mediators in bronchial asthma Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015 Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge Source: Eur Respir J 2010; 36: 1088-1098 Year: 2010 Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-β1 and LTE4 on human bronchial epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006 Imbalance of anti-inflammatory (resolving D1) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Role of anti-inflammatory treatments in complex chronic comorbidities Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Analysis of P2Y12 receptor responsiveness to cysteinyl leukotrienes Source: Annual Congress 2011 - Asthma: basic science and clinical studies Year: 2011 Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006 Role of leukotrienes in airway inflammation Source: Annual Congress 2004 - Early management of inflammatory airway diseases - Can we do better? Year: 2004 Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Resolution of inflammation in airway diseases Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014